86 related articles for article (PubMed ID: 24682196)
1. Mosapride (5HT4 agonist) in the treatment of blepharospasm.
Piyasena IN; Jayasinghe JA
Ceylon Med J; 2014 Mar; 59(1):26-7. PubMed ID: 24682196
[No Abstract] [Full Text] [Related]
2. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease.
Ruth M; Hamelin B; Röhss K; Lundell L
Aliment Pharmacol Ther; 1998 Jan; 12(1):35-40. PubMed ID: 9692698
[TBL] [Abstract][Full Text] [Related]
3. Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry.
Cho YK; Choi MG; Park EY; Lim CH; Kim JS; Park JM; Lee IS; Kim SW; Choi KY
Dig Dis Sci; 2013 Apr; 58(4):1035-41. PubMed ID: 23053900
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review.
Liu Q; Feng CC; Wang EM; Yan XJ; Chen SL
World J Gastroenterol; 2013 Dec; 19(47):9111-8. PubMed ID: 24379638
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized trial of mosapride vs. placebo in constipation-predominant irritable bowel syndrome.
Mansour NM; Ghaith O; El-Halabi M; Sharara AI
Am J Gastroenterol; 2012 May; 107(5):792-3. PubMed ID: 22552247
[No Abstract] [Full Text] [Related]
6. Mosapride for gastroesophageal reflux disease in neurologically impaired patients.
Komura M; Kanamori Y; Tanaka Y; Kodaka T; Sugiyama M; Terawaki K; Suzuki K; Iwanaka T
Pediatr Int; 2017 Mar; 59(3):347-351. PubMed ID: 27561215
[TBL] [Abstract][Full Text] [Related]
7. Mosapride treatment for functional dyspepsia: a meta-analysis.
Bang CS; Kim JH; Baik GH; Kim HS; Park SH; Kim EJ; Kim JB; Suk KT; Yoon JH; Kim YS; Kim DJ
J Gastroenterol Hepatol; 2015 Jan; 30(1):28-42. PubMed ID: 25041564
[TBL] [Abstract][Full Text] [Related]
8. The effect of mosapride citrate on constipation in patients with diabetes.
Ueno N; Inui A; Satoh Y
Diabetes Res Clin Pract; 2010 Jan; 87(1):27-32. PubMed ID: 19889470
[TBL] [Abstract][Full Text] [Related]
9. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.
Asai H; Udaka F; Hirano M; Minami T; Oda M; Kubori T; Nishinaka K; Kameyama M; Ueno S
Parkinsonism Relat Disord; 2005 Dec; 11(8):499-502. PubMed ID: 16263322
[TBL] [Abstract][Full Text] [Related]
10. Addition of prokinetic therapy to a PPI in reflux diseases.
Hsu YC; Lin HJ
Aliment Pharmacol Ther; 2011 Apr; 33(8):983-4; author reply 984-5. PubMed ID: 21434953
[No Abstract] [Full Text] [Related]
11. The 5-HT4 receptor agonist mosapride attenuates inflammation of reflux esophagitis.
Zhuang ZH; Zou FM; Tang DP; Zhuang JY; Wei JJ; Yang LY
Hepatogastroenterology; 2014; 61(129):115-9. PubMed ID: 24895805
[TBL] [Abstract][Full Text] [Related]
12. [Serotonin 5- HT4 receptor agonist (mosapride citrate)].
Odaka T; Suzuki T; Seza A; Yamaguchi T; Saisho H
Nihon Rinsho; 2006 Aug; 64(8):1491-4. PubMed ID: 16898619
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of mosapride citrate and lansoprazole for prevention of aspiration pneumonia in patients receiving gastrostomy feeding.
Takatori K; Yoshida R; Horai A; Satake S; Ose T; Kitajima N; Yoneda S; Adachi K; Amano Y; Kinoshita Y
J Gastroenterol; 2013 Oct; 48(10):1105-10. PubMed ID: 23238778
[TBL] [Abstract][Full Text] [Related]
14. Effects of mosapride on secondary peristalsis in patients with ineffective esophageal motility.
Chen CL; Yi CH; Liu TT; Orr WC
Scand J Gastroenterol; 2013 Dec; 48(12):1363-70. PubMed ID: 24099237
[TBL] [Abstract][Full Text] [Related]
15. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
Liu Z; Sakakibara R; Odaka T; Uchiyama T; Uchiyama T; Yamamoto T; Ito T; Asahina M; Yamaguchi K; Yamaguchi T; Hattori T
Mov Disord; 2005 Jun; 20(6):680-6. PubMed ID: 15719424
[TBL] [Abstract][Full Text] [Related]
16. Mosapride in gastrointestinal disorders.
Curran MP; Robinson DM
Drugs; 2008; 68(7):981-91. PubMed ID: 18457463
[TBL] [Abstract][Full Text] [Related]
17. Cinitapride-induced exanthema.
González Gutiérrez ML; Rubio Pérez M; Vázquez Cortés S; Martínez González de Lema B
J Investig Allergol Clin Immunol; 2010; 20(2):174. PubMed ID: 20461977
[No Abstract] [Full Text] [Related]
18. Effect of mosapride on recovery of intestinal motility after hand-assisted laparoscopic colectomy for carcinoma.
Narita K; Tsunoda A; Takenaka K; Watanabe M; Nakao K; Kusano M
Dis Colon Rectum; 2008 Nov; 51(11):1692-5. PubMed ID: 18584249
[TBL] [Abstract][Full Text] [Related]
19. Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 receptor agonist mosapride.
Nakamura M; Ohmiya N; Miyahara R; Ando T; Watanabe O; Kawashima H; Itoh A; Hirooka Y; Niwa Y; Goto H
Hepatogastroenterology; 2011; 58(106):453-8. PubMed ID: 21661412
[TBL] [Abstract][Full Text] [Related]
20. Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapy.
Nandurkar S
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1165-7. PubMed ID: 18699977
[No Abstract] [Full Text] [Related]
[Next] [New Search]
